Highlights

  • Lumos Diagnostics has appointed Magnamed LDA, a 30-year-old Portuguese medical device distributor, as its non-exclusive FebriDx® distribution partner in Portugal.
  • Magnamed placed an initial stocking order to support immediate commercial availability across its network of over 300 primary care, urgent care and hospital customers.
  • The appointment completes Lumos's Iberian coverage following the Alpha Medical Partnership in Spain in July 2026.
  • FebriDx® is now supported by distribution agreements across seven European countries including the UK, Greece, Romania, the Baltics, the Netherlands, Spain and Portugal.

Lumos Diagnostics Holdings Limited (ASX:LDX) has further expanded its European commercial network for FebriDx®, announcing a non-exclusive distribution agreement with Magnamed LDA for the Portuguese market. The appointment of Magnamed, an established Portuguese medical device company with over three decades of commercial history and a customer base of over 300 healthcare providers across the country's public and private health systems, rounds out Lumos's Iberian Peninsula coverage following the earlier appointment of Alpha Medical in Spain in July 2026. Magnamed operates with a team of dedicated sales specialists and maintains logistics infrastructure that supports consistent product delivery and customer servicing across Portugal's primary care, urgent care and hospital sectors. The distributor placed an initial stocking order at the time of agreement execution, ensuring FebriDx® is immediately available for order by its established customer base and demonstrating its intention to begin active commercialisation promptly.

FebriDx® as a Clinical Stewardship Tool

FebriDx® is a rapid, point-of-care diagnostic test addressing a specific and clinically important challenge in acute respiratory care: the timely differentiation of bacterial from viral infection in febrile patients. The clinical stakes in this differentiation are well documented. Prescribing antibiotics for a viral infection provides no therapeutic benefit to the patient while contributing to antimicrobial resistance — a public health concern that health systems worldwide are actively seeking to address through antimicrobial stewardship programmes. Conventional management without a rapid test often defaults to empirical antibiotics, particularly in time-pressured primary care and urgent care settings where laboratory culture results take days. FebriDx® offers a point-of-care result that can inform the prescribing decision in the same clinical encounter, supporting a more targeted and evidence-based approach. The test's ability to operate without laboratory infrastructure makes it particularly well suited to the community and urgent care settings in which it is primarily being deployed across the European distribution network.

Building a Broad European Network

The Magnamed agreement is the latest step in Lumos Diagnostics' systematic effort to build a geographically broad European presence for FebriDx® through a network of experienced regional distribution partners. This model — engaging established local distributors rather than building a direct European sales force — is a common and capital-efficient approach for medical device companies at Lumos's stage of development, allowing the company to access established customer relationships and market knowledge without the overhead of a large direct sales operation in multiple countries. The European network now covers seven distinct markets: the United Kingdom, Greece, Romania, the Baltic states, the Netherlands, Spain and Portugal. Each new partnership incrementally expands the addressable commercial opportunity for FebriDx® in Europe as market awareness of the product grows and reimbursement pathways develop within individual healthcare systems. Lumos's Managing Director described the ongoing expansion as an extension of a consistent strategy to broaden access through partners with proven regional healthcare credentials.

Lumos's Broader Portfolio and Strategic Direction

FebriDx® sits within a broader Lumos Diagnostics portfolio that includes proprietary digital reader platforms, customised assay development and Manufacturing services for third-party clients, and other point-of-care diagnostic tests targeting infectious and inflammatory disease indications. The company operates from facilities in both Australia and the United States, with commercial and development activities spanning both geographies. The core strategic thesis underpinning Lumos's market positioning is that point-of-care diagnostics are increasingly valued in modern healthcare for their ability to generate actionable clinical information at the time and place of patient contact, reducing delays, unnecessary referrals and inappropriate treatment decisions. As healthcare systems under pressure seek to improve the efficiency and quality of acute care, rapid diagnostic tools with clinically validated performance profiles are well positioned to gain broader adoption — provided they can be supported by appropriate distribution, reimbursement and clinical awareness infrastructure in target markets.

Key Insights

The Magnamed appointment completes a logical geographic step by giving Lumos distribution presence across both countries in the Iberian Peninsula, following the Spain appointment earlier in 2026. Building out the European network through experienced regional partners is a measured commercial strategy that allows market development to proceed without the Capital intensity of a direct salesforce model. The more consequential commercial question for investors is whether these distribution relationships translate into growing unit volumes and repeat consumable sales over time — a progression that will be tracked through the company's quarterly commercial reporting and any future European Revenue milestones.